

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines).

A notice listing all currently HHS-certified laboratories and IITFs is published in the **Federal Register** during the first week of each month. If any laboratory or IITF certification is suspended or revoked, the laboratory or IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory or IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at <http://www.samhsa.gov/workplace>.

FOR FURTHER INFORMATION CONTACT: Charles LoDico, Division of Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N02C, Rockville, Maryland 20857; 240-276-2600 (voice).

SUPPLEMENTARY INFORMATION: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April 30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).

The Mandatory Guidelines were initially developed in accordance with

Executive Order 12564 and section 503 of Public Law 100-71. The "Mandatory Guidelines for Federal Workplace Drug Testing Programs," as amended in the revisions listed above, requires strict standards that laboratories and IITFs must meet in order to conduct drug and specimen validity tests on urine specimens for federal agencies.

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

HHS-Certified Instrumented Initial Testing Facilities

Dynacare, 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-1190, (Formerly: Gamma-Dynacare Medical Laboratories).

HHS-Certified Laboratories

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844-486-9226.
 Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.).
 Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.).
 Baptist Medical Center-Toxicology Laboratory, 11401 I-30, Little Rock, AR 72209-7056, 501-202-2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).
 Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS, 66215-2802, 800-445-6917.
 DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-235-4890.

Dynacare*, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-1630, (Formerly: Gamma-Dynacare Medical Laboratories).
 ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662-236-2609.
 Laboratory Corporation of America Holdings, 7207 N Gessner Road, Houston, TX 77040, 713-856-8288/800-800-2387.
 Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical Laboratories, Inc.).
 Laboratory Corporation of America Holdings, 1904 TW Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group).
 Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).
 LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.).
 MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651-636-7466/800-832-3244.
 Legacy Laboratory Services—MetroLab, 1225 NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295.
 Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088. Testing for Veterans Affairs (VA) Employees Only.
 National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250/800-350-3515.
 One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
 Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory).
 Pathology Associates Medical Laboratories, 110 West Cliff Dr.,

Spokane, WA 99204, 509-755-8991/
800-541-7891x7.

Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888-
635-5840.

Quest Diagnostics Incorporated, 1777
Montreal Circle, Tucker, GA 30084,
800-729-6432, (Formerly: SmithKline
Beecham Clinical Laboratories;
SmithKline Bio-Science Laboratories).

Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-
Science Laboratories).

Redwood Toxicology Laboratory, 3700
Westwind Blvd., Santa Rosa, CA
95403, 800-255-2159.

STERLING Reference Laboratories, 2617
East L Street, Tacoma, WA 98421,
800-442-0438.

US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-
5235, 301-677-7085, Testing for
Department of Defense (DoD)
Employees Only.

* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS' NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (**Federal
Register**, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the **Federal
Register** on January 23, 2017 (82 FR
7920). After receiving DOT certification,
the laboratory will be included in the
monthly list of HHS-certified
laboratories and participate in the NLCP
certification maintenance program.

Charles P. LoDico,
Chemist.

[FR Doc. 2018-16440 Filed 7-31-18; 8:45 am]

BILLING CODE 4160-20-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[CBP Dec. 18-08]

COBRA Fees To Be Adjusted for Inflation in Fiscal Year 2019

AGENCY: U.S. Customs and Border
Protection, Department of Homeland
Security.

ACTION: General notice.

SUMMARY: This document announces
that U.S. Customs and Border Protection
(CBP) is adjusting certain customs user
fees and limitations established by the
Consolidated Omnibus Budget
Reconciliation Act (COBRA) for Fiscal
Year 2019 in accordance with the Fixing
America's Surface Transportation Act
(FAST Act) as implemented by CBP
regulations.

DATES: The adjusted amounts of
customs COBRA user fees and their
corresponding limitations set forth in
this notice for Fiscal Year 2019 are
required as of October 1, 2018.

FOR FURTHER INFORMATION CONTACT: Tina
Ghiladi, Director—Office of Finance,
202-344-3722, [UserFeeNotices@
cbp.dhs.gov](mailto:UserFeeNotices@cbp.dhs.gov).

SUPPLEMENTARY INFORMATION:

Background

On December 4, 2015, the Fixing
America's Surface Transportation Act
(FAST Act, Pub. L. 114-94) was signed
into law. Section 32201 of the FAST Act
amended section 13031 of the
Consolidated Omnibus Budget
Reconciliation Act (COBRA) of 1985 (19
U.S.C. 58c) by requiring certain customs
COBRA user fees and corresponding
limitations to be adjusted by the
Secretary of the Treasury (Secretary) to
reflect certain increases in inflation.

Sections 24.22 and 24.23 of title 19 of
the Code of Federal Regulations (19 CFR
24.22 and 24.23) describe the
procedures that implement the
requirements of the FAST Act.
Specifically, paragraph (k) in section
24.22 (19 CFR 24.22(k)) sets forth the
methodology to determine the change in
inflation as well as the factor by which
the fees and limitations will be adjusted,
if necessary. The fees and limitations
subject to adjustment, which are set
forth in Appendix A and Appendix B of
part 24, include the commercial vessel
arrival fees, commercial truck arrival
fees, railroad car arrival fees, private
vessel arrival fees, private aircraft
arrival fees, commercial aircraft and
vessel passenger arrival fees, dutiable
mail fees, customs broker permit user

fees, barges and other bulk carriers
arrival fees, and merchandise processing
fees, as well as the corresponding
limitations.

Determination of Whether an Adjustment Is Necessary for Fiscal Year 2019

In accordance with 19 CFR 24.22, CBP
must determine annually whether the
fees and limitations must be adjusted to
reflect inflation. For fiscal year 2019,
CBP is making this determination by
comparing the average of the Consumer
Price Index—All Urban Consumers, U.S.
All items, 1982-84 (CPI-U) for the
current year (June 2017–May 2018) with
the average of the CPI-U for the
comparison year (June 2016–May 2017)
to determine the change in inflation, if
any. If there is an increase in the CPI of
greater than one (1) percent, CBP must
adjust the customs COBRA user fees and
corresponding limitations using the
methodology set forth in 19 CFR
24.22(k). (19 CFR 24.22(k)). Following
the steps provided in paragraph (k)(2) of
section 24.22, CBP has determined that
the increase in the CPI between the most
recent June to May 12-month period
(June 2017–May 2018) and the
comparison year (June 2016–May 2017)
is 2.063¹ percent. As the increase in the
CPI is greater than one (1) percent, the
customs COBRA user fees and
corresponding limitations must be
adjusted for Fiscal Year 2019.

Determination of the Adjusted Fees and Limitations

Using the methodology set forth in
section 24.22(k)(2) of the CBP
regulations (19 CFR 24.22(k)), CBP has
determined that the factor by which the
base fees and limitations will be
adjusted is 4.866 percent (base fees and
limitations can be found in Appendix A
and B to part 24 of title 19). In reaching
this determination, CBP calculated the
values for each variable found in
paragraph (k) of 19 CFR 24.22 as
follows:

- The arithmetic average of the CPI-U for June 2017–May 2018, referred to as (A) in the CBP regulations, is 247.540;
- The arithmetic average of the CPI-U for Fiscal Year 2014, referred to as (B), is 236.009;
- The arithmetic average of the CPI-U for the comparison year, referred to as (C), is 242.328;
- The difference between the arithmetic averages of the CPI-U of the

¹ The figures provided in this notice may be rounded for publication purposes only. The calculations for the adjusted fees and limitations were made using unrounded figures, unless otherwise noted.